ReviewCNS oncology2014
Molecular and genetic pathways in gliomas: the future of personalized therapeutics.
Review in CNS oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- The Expression Pattern and Clinical Significance of Lysyl Oxidase Family in Gliomas.Doklady. Biochemistry and biophysics · 2023Article
- The Glioma-IRE project - Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach.Journal of translational medicine · 2023Article
- MiR-4310 induced by SP1 targets PTEN to promote glioma progression.Cancer cell international · 2020Article
- Long noncoding RNA FTX is associated with prognosis of glioma patients.The journal of gene medicine · 2020Article
- From astrocytoma to glioblastoma: a clonal evolution study.FEBS open bio · 2020Article
- BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China.Frontiers in oncology · 2020Article
- A prognostic signature based on three non-coding RNAs for prediction of the overall survival of glioma patients.FEBS open bio · 2019Article
- Roles of Oncogenic Long Non-coding RNAs in Cancer Development.Genomics & informatics · 2018Article
- Article
- Expression Profile of MiR-128 in the Astrocytoma Patients and Cell Lines.Molecular neurobiology · 2016Article
- Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.Journal of neuro-oncology · 2015Review
- Genomic discoveries in adult astrocytoma.Current opinion in genetics & development · 2015Review
- Robustness of equations that define molecular subtypes of glioblastoma tumors based on five transcripts measured by RT-PCR.Omics : a journal of integrative biology · 2015Article
- Tc-99m Glucoheptonate Single Photon Emission Computed Tomography-Computed Tomography for Detection of Recurrent Glioma: A Prospective Comparison with N-13 Ammonia Positron Emission Tomography-Computed Tomography.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last few decades, we have seen significant advances in brain imaging, which have resulted in more detailed anatomic and functional localization of gliomas in relation to the eloquent cortex, as well as improvements in microsurgical techniques and enhanced delivery of adjuvant stereotactic radiation. While these advancements have led to a relatively modest improvement in clinical outcomes for patients with malignant gliomas, much more work remains to be done. As with other types of cancer, we are now rapidly moving past the era of histopathology dictating treatment for brain tumors and into the realm of molecular diagnostics and associated targeted therapies, specifically based on the genomic architecture of individual gliomas. In this review, we discuss the current era of molecular glioma characterization and how these profiles will allow for individualized, patient-specific targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.